CDT Equity Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and advancing therapeutic assets through scientific innovation and strategic partnerships. CDT Equity Inc. develops clinical-stage programs across autoimmune diseases, oncology, dermatology, idiopathic male infertility, rare diseases, and animal health. Its current portfolio includes compounds such as AZD1656, AZD5658, and AZD5904, supported by an approach that combines artificial intelligence, solid-form chemistry, and asset repositioning to improve development efficiency. The company emphasizes value creation through intellectual property, out-licensing, and partnerships rather than large-scale internal drug development. CDT Equity Inc. serves as a specialized participant in the healthcare sector, aiming to bring differentiated treatment candidates into clinical and commercial pathways.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. David Joszef Tapolczay
- Employees
- 7
- Headquarters
- San Diego, CA, United States
- Website
- www.conduitpharma.com